natgillin/translations-raw huggingface dataset:
Hvis psykiatriske symptomer vedvarer eller forværres, eller selvmordstanker identificeres, anbefales det, at behandling med Ribavirin og peginterferon alfa-2b eller interferon alfa-2b afbrydes, og at patienten følges, og psykiatrisk intervention institueres ved behov.
If psychiatric symptoms persist or worsen, or suicidal ideation is identified, it is recommended that treatment with Ribavirin and peginterferon alfa-2b or interferon alfa-2b be discontinued, and the patient followed, with psychiatric intervention as appropriate.
Hvis psykiatriske symptomer vedvarer eller forværres, eller selvmordstanker identificeres, anbefales det, at behandling med Ribavirin Teva Pharma B.V. og peginterferon alfa-2b eller interferon alfa-2b afbrydes, og at patienten følges, og psykiatrisk intervention institueres efter behov.
If psychiatric symptoms persist or worsen, or suicidal ideation is identified, it is recommended that treatment with Ribavirin Teva Pharma B.V. and peginterferon alfa-2b or interferon alfa-2b be discontinued, and the patient followed, with psychiatric intervention as appropriate.
Hvis psykiatriske symptomer vedvarer eller forværres, eller selvmordstanker identificeres, anbefales det, at behandling med Viraferon afbrydes, og patienten følges med passende psykiatrisk intervention.
symptoms persist or worsen, or suicidal ideation is identified, it is recommended that treatment with Viraferon be discontinued, and the patient followed, with psychiatric intervention as appropriate.
Hvis psykiatriske symptomer vedvarer eller forværres, eller selvmordstanker identificeres, anbefales det, at Viraferon behandling afbrydes, og at patienten følges med passende psykiatrisk intervention.
symptoms persist or worsen, or suicidal ideation is identified, it is recommended that treatment with Viraferon be discontinued, and the patient followed, with psychiatric intervention as appropriate.
Hvis PTH-niveauet falder til under det anbefalede målområde hos patienter, der behandles med Parareg, skal dosen af Parareg og/eller D- vitamin-steroler reduceres, eller behandlingen skal afbrydes.
If PTH levels decrease below the recommended target range in patients treated with Parareg, the dose of Parareg and/or vitamin D sterols should be reduced or therapy discontinued.
Hvis pulveret fra en knækket kapsel med Imnovid får kontakt med huden, vaskes huden straks grundigt med sæbe og vand.
If powder from a broken Imnovid capsule makes contact with the skin, wash the skin immediately and thoroughly with soap and water.
Hvis pulveret til opblanding af en oral suspension ikke fås, kan apotekeren fremstille en opløsning ved hjælp af Ebilfumin-kapslerne, eller kapslernes indhold kan blandes i sødede madvarer hjemme.
If the powder for oral suspension is not available, the pharmacist can make up a solution using the contents of Ebilfumin capsules, or the contents of the capsules can be mixed into sweetened food at home.
Hvis pulveret til opblanding af en oral suspension ikke fås, kan apotekeren fremstille en opløsning ved hjælp af kapslernes indhold, eller kapslernes indhold kan blandes i sødede madvarer hjemme.
If the powder for oral suspension is not available, the pharmacist can make up a solution using the contents of the capsules, or the contents of the capsules can be mixed into sweetened food at home.
Hvis pumpen mister evnen til at pumpe (der kommer ikke gel ud, når pumpen trykkes ned), skal du forberede pumpen igen ved at gentage den ovenfor beskrevne proces.
If prime is lost during the use (no gel is dispensed after depressing the pump), repeat as instructed above to re-prime the pump.
Hvis påkrævet kan Grastofil fortyndes i 5 % glucose.
If required, Grastofil may be diluted in 5% glucose.
Hvis påkrævet, bør dosis af det antidiabetiske lægemiddel justeres under behandling med andre lægemidler og ved denne behandlings ophør.
If necessary, the dosage of the antihyperglycaemic medicinal product should be adjusted during therapy with the other medicinal product and on its discontinuation.
Hvis påkrævet, bør dosis af det antidiabetiske lægemiddel justeres under behandling med andre lægemidler og ved dets ophør.
If necessary, the dosage of the antihyperglycaemic medicinal product should be adjusted during therapy with the other medicinal product and on its discontinuation.
Hvis QT-intervallet er > 500 msek. frarådes det at anvende Fareston.
If the QTc interval is > 500 ms, Fareston should not be used.
Hvis QTc-intervallets varighed overstiger 450/470 ms for mandlige/kvindelige patienter under delamanid- behandlingen, skal disse patienter have hyppigere EKG-overvågning.
If the QTc interval duration exceeds 450/470 ms for male/female patients during delamanid treatment, these patients should be administered more frequent ECG monitoring.
Hvis Rapiscan indgives, bør kvinden ikke amme i mindst 10 timer (dvs. mindst 5 gange eliminationshalveringstiden i plasma) efter indgivelsen af Rapiscan.
If Rapiscan is administered, the woman should not breast-feed for at least 10 hours (that is, at least 5 times the plasma elimination half-life) following Rapiscan administration.
Hvis Rasitrio anvendes under amning, bør dosis holdes så lav som muligt.
If Rasitrio is used during breast- feeding, doses should be kept as low as possible.
Hvis reaktionen er svær, vil lægen stoppe den intravenøse infusion med det samme og begynde at give dig passende medicinsk behandling.
If the reaction is severe, your doctor will stop the intravenous infusion immediately and start giving you appropriate medical treatment.
Hvis reaktionerne er svære, og/eller virkningen af medicinen er nedsat, vil lægen tage en blodprøve for at tjekke for antistoffer, der kan påvirke behandlingsresultatet.
If the reactions are severe and/or there is a loss of effect from this medicine, your doctor will perform a blood test to check for antibodies which may affect the outcome of your treatment
Hvis rekonstituering og fortynding er udført under aseptiske forhold, skal infusion med NULOJIX påbegyndes straks eller inden for 24 timer efter rekonstituering.
When reconstitution and dilution are performed under aseptic conditions, the NULOJIX infusion should be started immediately or must be completed within 24 hours of reconstitution of the powder.
Hvis resultaterne af testene tydeligt indikerer resistens over for et bestemt anthelmintikum, skal der bruges et anthelmintikum, som tilhører en anden farmakologisk klasse, og som har en anden virkningsmekanisme.
Where the results of the tests strongly suggest resistance to a particular anthelmintic, an anthelmintic belonging to another pharmacological class and having a different mode of action should be used.
Hvis resultaterne fra de visuelle og anatomiske undersøgelser indikerer, at patienten ikke har gavn af fortsat behandling, skal Eylea seponeres
If visual and anatomic outcomes indicate that the patient is not benefiting from continued treatment, Eylea should be discontinued.
Hvis resultaterne fra de visuelle og anatomiske undersøgelser indikerer, at patienten ikke har gavn af fortsat behandling, skal Eylea seponeres.
If visual and anatomic outcomes indicate that the patient is not benefiting from continued treatment, Eylea should be discontinued.
Hvis resultatet af behandlingen er tilfredsstillende, sænkes dosis til en halv tablet om dagen.
If treatment is successful lower the dose to half a tablet a day.
Hvis Retacrit indsprøjtes under huden (subkutant), bør den mængde, der indsprøjtes på ét sted, ikke overstige 1 ml.
If Retacrit is injected under the skin, the amount injected in any one place should not exceed 1 ml.
Hvis Retacrit indsprøjtes under huden (subkutant), kan De også selv foretage indsprøjtningen når De har fået vist, hvordan det skal gøres.
In case Retacrit is injected under the skin (subcutaneously) you can also inject the solution yourself once you have been shown how.
hvis REYATAZ administreres
exercised if REYATAZ is co
hvis REYATAZ/ritonavir
exercised if
Hvis REYATAZ/ritonavir administreres samtidig med irinotecan, bør patienten monitoreres tæt for irinotecan- relaterede bivirkninger.
If REYATAZ/ritonavir is co- administered with irinotecan, patients should be closely monitored for adverse events related to irinotecan.
Hvis ribavirin seponeres permanent mhp. behandling af anæmi, skal INCIVO ligeledes seponeres permanent.
If ribavirin is permanently discontinued for the management of anaemia, INCIVO must also be permanently discontinued.
Hvis risikofaktorer for hypoglykæmi er til stede (herunder nedsat nyrefunktion, lav kropsvægt, fejlernæring, samtidig administration med visse lægemidler (se afsnit 4.5) eller livsstilsændringer), kan det være nødvendigt at gå over til samtidig behandling med enkeltstofferne og en reduktion af glimepirid dosis kan være nødvendig.
If risk factors for hypoglycaemia are present (including renal insufficiency, low body weight, malnourishment, co-administration with certain other medicinal products (see section 4.5) or if the patient’s life-style changes) it may be necessary to revert to concomitant therapy and down titrate the glimepiride dose.
Hvis risikohåndteringssystemet ændres eller der modtages nye oplysninger, der kan føre til signifikante ændringer i fordele/risici-balancen af lægemidlet, eller som følge af, at en vigtig milepæl (minimering af bivirkninger eller risici) passeres.
Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.
Hvis risikostyringsplanen modificeres og specielt, hvis ny information, som kan føre til en signifikant ændring i fordel/risiko-profilen, er fremkommet, eller hvis en afgørende (lægemiddelovervågning eller risikominimering) milepæl er nået.
Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.
Hvis rituximab anvendes i kombination med Bortezomib Hospira, skal patienter med risiko for HBV- infektion altid screenes for HBV, inden behandlingen startes.
When rituximab is used in combination with Bortezomib Hospira, HBV screening must always be performed in patients at risk of infection with HBV before initiation of treatment.
Hvis Rivastigmine 3M Health Care Ltd. depotplasteret falder af
What to do if a patch falls off
Hvis rosiglitazon anvendes i kombination med metformin og insulin, anbefales det at øge overvågningen af patienten.
Increased monitoring of the patient is recommended if rosiglitazone is used in combination with metformin and insulin.
Hvis samtidig administration af
If the co-administration of atazanavir with an NNRTI is required, an
Hvis samtidig administration af atazanavir
If the co- administration of atazanavir with an NNRTI is required, an
Hvis samtidig administration af atazanavir
If the co-administration of atazanavir with an NNRTI is required, an
Hvis samtidig administration af atazanavir og et NNRTI er nødvendig, bør det
If the co- administration of atazanavir with an NNRTI is required, an
Hvis samtidig administration af den kraftige CYP2C8-hæmmer stoppes, bør dosis af enzalutamid ændres tilbage til den dosis, der blev anvendt inden initiering af den kraftige CYP2C8- hæmmer (se pkt.
If co-administration of the strong CYP2C8 inhibitor is discontinued, the enzalutamide dose should be returned to the dose used prior to initiation of the strong CYP2C8 inhibitor (see section 4.5).
Hvis samtidig administration af ketoconazol, eller andre potente CYP3A4- hæmmere, og aripiprazol overvejes, bør eventuelle fordele opveje potentielle risici for patienten.
When considering concomitant administration of ketoconazole or other potent CYP3A4 inhibitors with aripiprazole, potential benefits should outweigh the potential risks to the patient.
Hvis samtidig administration af ketoconazol, eller andre potente CYP3A4- hæmmere, og Aripiprazole overvejes, bør eventuelle fordele opveje potentielle risici for patienten.
When considering concomitant administration of ketoconazole or other potent CYP3A4 inhibitors with aripiprazole, potential benefits should outweigh the potential risks to the patient.
Hvis samtidig administration af ketoconazol, eller andre potente CYP3A4-hæmmere, og aripiprazol overvejes, bør eventuelle fordele opveje potentielle risici for patienten.
When considering concomitant administration of ketoconazole or other potent CYP3A4 inhibitors with aripiprazole, potential benefits should outweigh the potential risks to the patient.
Hvis samtidig administration af lopinavir/ritonavir med bupropion vurderes at være uundgåelig, bør dette, på trods af den observerede induktion, gøres under nøje klinisk overvågning af bupropions effekt uden at overskride den anbefalede dosis.
If the co-administration of lopinavir/ritonavir with bupropion is judged unavoidable, this should be done under close clinical monitoring for bupropion efficacy, without exceeding the recommended dosage, despite the observed induction.
Hvis samtidig administration af potente CYP3A- hæmmere ikke kan undgås, skal patienterne overvåges omhyggeligt med hensyn til sikkerhed.
If concomitant use of a strong CYP3A inhibitor is unavoidable, patients should be carefully monitored for safety.
Hvis samtidig administration af potente eller moderate CYP3A-inhibitorer er nødvendig, bør dosis af olaparib reduceres.
If the strong or moderate CYP3A inhibitors must be co- administered, the dose of olaparib should be reduced.
Hvis samtidig administration af specifik hepatitis B- immunoglobulin og Fendrix er påkrævet, skal der anvendes forskellige injektionssteder.
If concomitant administration of specific hepatitis B immunoglobulin and Fendrix is required, these should be given at different injection sites.
Hvis samtidig administration af sådanne lægemidler og bedaquilin skønnes nødvendig, anbefales klinisk monitorering inklusive hyppig EKG-vurdering.
In the event that co-administration of such medicinal products with bedaquiline is necessary, clinical monitoring including frequent electrocardiogram assessment is recommended.
Hvis samtidig administration anses for nødvendig, skal Epclusa administreres sammen med mad og tages 4 timer før protonpumpehæmmeren.
If it is considered necessary to co-administer, then Epclusa should be administered with food and taken
Hvis samtidig administration derfor anses for uundgåelig for at sammensætte en tilstrækkelig behandling af MDR-TB, anbefales det at udføre hyppig overvågning af EKG under hele behandlingsperioden med delamanid.
Therefore if co- administration is considered to be unavoidable in order to construct an adequate treatment regimen for MDR- TB it is recommended that there is very frequent monitoring of ECGs throughout the full delamanid treatment period.
Hvis samtidig administration ikke kan undgås, bør CK- værdier måles regelmæssigt mere end én gang om ugen, og patienterne bør overvåges tæt for ethvert tegn eller symptom, som kan tyde på myopati.
If co-administration cannot be avoided, CPK levels should be measured more frequently than once weekly and patients should be closely monitored for any signs or symptoms that might represent myopathy.
Hvis samtidig administration med
If co-administration with rifampicin is unavoidable, a
Hvis samtidig administration med rifampicin er uundgåelig, kan en dobbelt dosis ISENTRESS dog overvejes hos voksne.
However, if co-administration with rifampicin is unavoidable, a doubling of the dose of ISENTRESS can be considered in adults.
Hvis samtidig behandling med en potent CYP3A4/5-hæmmer afbrydes, bør det overvejes at vende tilbage til den oprindelige axitinib-dosis (se pkt.
If co-administration of the strong inhibitor is discontinued, a return to the axitinib dose used prior to initiation of the strong CYP3A4/5 inhibitor should be considered (see section 4.5).
Hvis samtidig behandling med en stærk CYP3A-hæmmer ikke kan undgås, skal dosis reduceres med ca. en tredjedel (dosis ikke klinisk verificeret), afrundet til den nærmeste dosis 150 mg-styrken går op i.
If concomitant use of a strong CYP3A inhibitor is unavoidable, reduce the dose by approximately one third (dose not clinically verified), rounded to the nearest multiple of the 150 mg dosage strength.
Hvis samtidig brug af
co-administration of PREZISTA
Hvis samtidig brug af Stribild og nefrotoksiske lægemidler er uundgåelig, skal nyrefunktionen monitoreres ugentligt.
If concomitant use of Stribild and nephrotoxic agents is unavoidable, renal function must be monitored weekly.
Hvis samtidig brug af stærke CYP3A-hæmmere ikke kan undgås (herunder, men ikke begrænset til, ritonavir, saquinavir, telithromycin, ketoconazol, itraconazol, voriconazol, posaconazol og nefazodon), skal dosis reduceres med ca. en tredjedel, afrundet til den nærmeste dosis 150 mg-styrken går op i.
If it is not possible to avoid concomitant use with strong CYP3A inhibitors (including, but not limited to, ritonavir, saquinavir, telithromycin, ketoconazole, itraconazole, voriconazole, posaconazole and nefazodone), reduce the ceritinib dose by approximately one third, rounded to the nearest multiple of the 150 mg dosage strength.
Hvis samtidig brug af tenofovirdisoproxilfumarat og nefrotoksiske lægemidler er uundgåelig, skal nyrefunktionen monitoreres ugentligt.
If concomitant use of tenofovir disoproxil fumarate and nephrotoxic agents is unavoidable, renal function should be monitored weekly.
Hvis samtidig brug af Truvada og nefrotoksiske lægemidler ikke kan undgås, bør nyrefunktionen monitoreres ugentligt.
If concomitant use of Truvada and nephrotoxic agents is unavoidable, renal function should be monitored weekly.
Hvis samtidig brug skønnes nødvendig, tilrådes regelmæssig kontrol af nyrefunktion inklusive serumelektrolytter i overensstemmelse med standardpraksis.
Consistent with standard medical practice, periodic determination of renal function including serum electrolytes is advised if co-administration is considered necessary.
Hvis samtidig vaccination med andre vacciner er nødvendigt, gives den anden vaccine i den anden arm.
However, if this cannot be avoided, the other vaccine will be injected into the other arm.
Hvis samtidig vaccination med andre vacciner er nødvendigt, gives den anden vaccine i den anden arm.
However, if this cannot be avoided, the vaccines should be injected into separate limbs.
Hvis samtidig vaccination med andre vacciner er nødvendigt, gives vaccinerne i hver sin arm.
However, if this cannot be avoided, the vaccines should be injected into separate limbs.
Hvis samtidig vaccination med andre vacciner er nødvendigt, vil vaccinerne blive givet i hver sin arm.
However, if this needs to happen, the other vaccine will be injected into the other arm.
Hvis saquinavir derfor gives sammen med ritonavir, skal de potentielle virkninger af ritonavir på andre lægemidler tages i betragtning (se produktresuméet for Norvir).
Therefore, when saquinavir is co-administered with ritonavir, consideration should be given to the potential effects of ritonavir on other medicinal products (see the Summary of Product Characteristics for Norvir).
Hvis scanningen kun viser få eller ingen β-amyloidplak, er det usandsynligt, at patienten har Alzheimers sygdom.
If few or no β-amyloid plaques are seen in the PET scan (a negative scan), the patient is unlikely to have Alzheimer’s disease.
Hvis selvinjektion opstår ved et uheld, bør der øjeblikkeligt søges læge og lægen informeres om at selvinjektion med en levende chlamydia vaccine er sket.
If self-injection occurs, immediate medical advice should be sought and the doctor informed that self-injection with a living chlamydial vaccine has occurred.
Hvis seponering af behandling med en af komponenterne i Atripla er indiceret, eller hvis dosismodificering er påkrævet, er separate efavirenz-, emtricitabin- og tenofovirdisoproxilfumarat-præparater tilgængelige.
Where discontinuation of therapy with one of the components of Atripla is indicated or where dose modification is necessary, separate preparations of efavirenz, emtricitabine and tenofovir disoproxil fumarate are available.
Hvis seponering af en af komponenterne i Atripla er indiceret, eller hvis modifikation af dosis er nødvendig, er separate præparater med efavirenz, emtricitabin og tenofovirdisoproxilfumarat tilgængelige.
Where discontinuation of therapy with one of the components of Atripla is indicated or where dose modification is necessary, separate preparations of efavirenz, emtricitabine and tenofovir disoproxil fumarate are available.
Hvis serum-natrium stiger ≥ 12 mmol/l inden for 24 timer eller ≥ 18 mmol/l inden for 48 timer, skal behandling med tolvaptan afbrydes eller seponeres hypoton væske administreres.
≥ 12 mmol/l within 24 hours or ≥ 18 mmol/l within 48 hours, tolvaptan treatment is to be interrupted or discontinued followed by administration of hypotonic fluid.
Hvis serum-natrium stiger ≥ 12 mmol/l inden for 24 timer eller ≥ 18 mmol/l inden for 48 timer, skal behandling med tolvaptan afbrydes eller seponeres og hypoton væske administreres.
≥ 12 mmol/l within 24 hours or ≥ 18 mmol/l within 48 hours, tolvaptan treatment is to be interrupted or discontinued followed by administration of hypotonic fluid.
Hvis serumcalcium falder til under 8,4 mg/dl (2,1 mmol/l), og/eller der opstår symptomer på hypokalcæmi, anbefales følgende behandling:
In the event that serum calcium levels fall below 8.4 mg/dl (2.1 mmol/l) and/or symptoms of hypocalcaemia occur the following management is recommended:
Hvis serumcreatinin under kombinationsbehandlingen med topotecan og cisplatin overstiger 132 μmol /l, anbefales det at konsultere den eksisterende information om cisplatin vedrørende dosisreduktion og fortsat behandling.
If, during topotecan/cisplatin combination therapy serum creatinine exceeds 132 μmol/l, it is recommended that the full prescribing information be consulted for any advice on cisplatin dose reduction/continuation.
Hvis serumhæmoglobin fortsatte med at falde til ≤5,3 mmol/l (≤8,5 g/dl), kunne forsøgspersonerne få behandling med ekstra anæmi-interventioner, herunder anvendelse af erythropoietin eller reduktion af ribavirindosis.
If serum haemoglobin concentrations continued to decrease to ≤ 8.5 g/dL, subjects could be treated with additional anaemia interventions, including the use of erythropoietin or ribavirin dose reduction.
Hvis serumkreatinin stiger til > 2 mg/dl (Tabel 3), skal ribavirin og interferon alfa-2b seponeres.
If serum creatinine rises to > 2 mg/dl (Table 3), ribavirin and interferon alfa-2b must be discontinued.
Hvis serumkreatinin stiger til > 2,0 mg/dl (Tabel 3), skal Ribavirin BioPartners og interferon alfa-2b seponeres.
If serum creatinine rises to > 2.0 mg/dl (Table 3), Ribavirin BioPartners and interferon alfa-2b must be discontinued.
Hvis serumkreatinin stiger til > 2,0 mg/dl (Tabel 3), skal ribavirin og interferon alfa-2b seponeres.
If serum creatinine rises to > 2.0 mg/dl (Table 3), ribavirin and interferon alfa-2b must be discontinued.
Hvis serumphosphat er < 1,5 mg/dl (0,48 mmol/l), eller kreatinin-clearance er reduceret til < 50 ml/min hos patienter, der får Emtricitabine/Tenofovir disoproxil Zentiva, bør nyrefunktionen revurderes inden for en uge, herunder måling af blodglucose, blodkalium og uringlucose (se pkt.
If serum phosphate is < 1.5 mg/dL (0.48 mmol/l) or creatinine clearance is decreased to < 50 ml/min in any patient receiving Emtricitabine/Tenofovir disoproxil Zentiva, renal function should be re- evaluated within one week, including measurements of blood glucose, blood potassium and urine glucose concentrations (see section 4.8, proximal tubulopathy).
Hvis sikkerhedsringen omkring hætten er løs, efter at hætten er fjernet, skal den tages af, før du bruger øjendråberne.
After cap is removed, if tamper evident snap collar is loose, remove before using the product.
Hvis sikkerhedsringen omkring hætten sidder løs, når flasken åbnes, skal den fjernes, inden præparatet tages i brug.
After the cap is removed, if the tamper evident snap collar is loose, remove before using product.